NextWave wins US FDA OK for liquid methylphenidate in ADHD
This article was originally published in Scrip
Executive Summary
The US FDA granted its approval for specialty pharma NextWave Pharmaceuticals to market Quillivant XR (methylphenidate hydrochloride) as a treatment for attention-deficit/hyperactivity disorder (ADHD).